View allAll Photos Tagged stemcells
Anne M. Petersen, EU consultant, creoDK, Capital Region Denmark EU Office
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Medical conferences bring together a powerful mixture of mature thought leaders and the next generation of experts with the sole goal of designing and completing the advancement in the arena of cancer science & Stem Cell Research that will change the way we do research in cancer science and stem cell field for the better. Medical conferences fill a critical need for pharmaceutical sponsors, providing an unparalleled level of strategic, scientific, and operational expertise in a timely manner.
An International Conference On cancer Science & Stem Cell Research
when-29-30 July, 2019
Where- Amsterdam, Netherlands
Contact : +31728080590
cancerscience@medicalconferences.nl
www.medicalconferences.nl/conference_registration/Cancer-...
Vincent Clay, Manager, EU Government Affairs & Stakeholder Engagement, EU Representation Office, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Motor neuron progenitors (green) derived from human embryonic stem cells. Such neurons could be used to treat spinal cord injuries and diseases of the motor neurons.
This photo was taken by Sharyn Rossi in the lab of Hans Keirstead at the University of California, Irvine.
Learn more about CIRM-funded stem cell research: www.cirm.ca.gov
Shamshad Ahmed of Smart Cells International explains stem cell treatment successes.www.smartcells.com
Paula Salmikangas:
· Senior Researcher. Finnish Medicines Agency. Helsinki, FINLAND
· Vice-Chair of the Committee for Advanced Therapies (CAT), EMA
· Chair of the Cell Products Working Party (CPWP), EMA
Katherine Littler, Policy Adviser, Wellcome Trust
Amelia Andersdotter, Member, European Parliament
Suchitra Sumitran-Holgersson, Professor of Transplantation Biology, University of Gothenburg
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
The Workshop on Treatment of Hematologic Malignancies and Allogeneic Hematopoietic Stem Cell Transplantation using Alternative Donors in September 2012 was a forum for the sharing of new knowledge and the building of bridges between researchers.
Phil Holliday, European Advisor, UK Research Office (UKRO)
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Jessica Cole, Assistant to Vicky Ford, MEP, European Parliament
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
The staff at Bauman Medical Group is proud to be among the first 100% complete hair transplant teams to become certified in FDA approved Autologel PRP for Hair Restoration Surgery and Wound Healing.
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Wing disc of a fruit fly. The larval wing disc is the source of cells that develop into wings. Fluorescent antibody stain (red) to the nuclear pore, which connects the cytoplasm to the nucleoplasm of the cell. The blue color is a fluorescent stain (DAPI) for DNA in the nucleus.
Event : Headshot & Product
Date : 29th March 2015 (13:30 - 18:00)
Location : U Delight @ OnNut Station
Model : Lookkate
Product : Fixx Stemcell Serum
FB : Fixx Stemcell Serum
IG : Fixx Stemcell Serum
Call : 086 0397 8847
Gallery : www.flickr.com/photos/photo_network_group/sets/
Join with Photo Network Group :-
Scientists move one step closer to “curing” diabetes using first-ever stem cell implant bit.ly/2wogwz5 #stemcells #science
Rob T. A. Janssen, Secretary-General, Alliance for Advanced Therapies
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Senator Chris Dodd and Congressman Chris Murphy (CT-5) joined stem cell researchers, doctors, patient advocates, and Connecticut residents suffering from diseases that may be helped through stem cell research to celebrate President Obama’s recent Executive Order overturning the restrictive stem cell policies put in place by President Bush. Dodd and Murphy were also joined by Cindy Tian, the widow of Dr. Xiangzhong “Jerry” Yang, head of the University of Connecticut’s Center for Regenerative Biology and leading stem cell researcher who passed away last month.
Amelia Andersdotter, Member, European Parliament
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
The University of Louisville Division of Cardiovascular Medicine presented the 21st Annual Leonard Leight Lecture on December 10, 2014 in Kornhauser Auditorium on the UofL Health Sciences campus.
The special guest speaker for 2014 was Victor J. Dzau, M.D., President of the Institute of Medicine.
Dr. Dzau presented "Molecular Approaches to Cardiac Regeneration" focusing on understanding cell-based therapy for cardiac regeneration.
Senator Chris Dodd and Congressman Chris Murphy (CT-5) joined stem cell researchers, doctors, patient advocates, and Connecticut residents suffering from diseases that may be helped through stem cell research to celebrate President Obama’s recent Executive Order overturning the restrictive stem cell policies put in place by President Bush. Dodd and Murphy were also joined by Cindy Tian, the widow of Dr. Xiangzhong “Jerry” Yang, head of the University of Connecticut’s Center for Regenerative Biology and leading stem cell researcher who passed away last month.
Keith Thompson, CEO, Cell Therapy Catapult Centre
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Lilli from work.
She is the nurse who performed the first Haematopoietic Stemcell Transplantation on an adult in Norway.
The stem cells are a quick growing space of medical analysis. Research into how stem cells will cure variety of conditions has been intensive over the past three decades and here at regenerative medicine institute they're proud to be at the forefront of breakthrough discoveries and coverings. www.americanhealthblogs.com/the-best-heart-failure-treatm...
Arnd Hoeveler, Head of Unit, Advanced Therapies and Systems Medicine, DG Research & Innovation, European Commission
Marina Yannakoudakis, Member, European Parliament
Keith Thompson, CEO, Cell Therapy Catapult Centre
Gil Beyen, Managing Director and Chief Business Officer, TiGenix
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen